Abstract
The present work was aimed that in vitro antioxidant activity of some novel synthetic mononuclear Ruthenium (II) compounds namely, Ru (1, 10-phenanthroline)2(2-nitro Phenyl thiosemicarbazone)Cl2 (compound R1) and Ru (1, 10- phenanthroline)2(2-hydroxy-phenyl thiosemicarbazone)Cl2 (compound R2) using [2, 29-azinobis-(3-ethylbenzothiazoline- 6-sulfonic acid)] (ABTS), Ferric reducing antioxidant power (FRAP), N, N-dimethyl-p-phenylenediamine (DMPD), 1, 1- diphenyl-2-picryl hydrazine (DPPH) and Nitro blue tetrazolium (NBT) assays. The results concluded that both the compounds (R1&R2) exhibited a significant antioxidant activity. But compared to reference standards, R1 was found to be better free radical scavenging activity than R2.
Keywords: Antioxidant, ABTS, DMPD, DPPH, FRAP, NBT, Ruthenium compounds
Letters in Drug Design & Discovery
Title:In Vitro Antioxidant Activity of Some Novel Synthetic Mononuclear Ruthenium (II) Compounds
Volume: 9 Issue: 4
Author(s): Shyam Sunder Anchuri, Sreekanth Thota, Rajeshwar Yerra, Satyavati Dhulipala
Affiliation:
Keywords: Antioxidant, ABTS, DMPD, DPPH, FRAP, NBT, Ruthenium compounds
Abstract: The present work was aimed that in vitro antioxidant activity of some novel synthetic mononuclear Ruthenium (II) compounds namely, Ru (1, 10-phenanthroline)2(2-nitro Phenyl thiosemicarbazone)Cl2 (compound R1) and Ru (1, 10- phenanthroline)2(2-hydroxy-phenyl thiosemicarbazone)Cl2 (compound R2) using [2, 29-azinobis-(3-ethylbenzothiazoline- 6-sulfonic acid)] (ABTS), Ferric reducing antioxidant power (FRAP), N, N-dimethyl-p-phenylenediamine (DMPD), 1, 1- diphenyl-2-picryl hydrazine (DPPH) and Nitro blue tetrazolium (NBT) assays. The results concluded that both the compounds (R1&R2) exhibited a significant antioxidant activity. But compared to reference standards, R1 was found to be better free radical scavenging activity than R2.
Export Options
About this article
Cite this article as:
Shyam Sunder Anchuri, Sreekanth Thota, Rajeshwar Yerra, Satyavati Dhulipala , In Vitro Antioxidant Activity of Some Novel Synthetic Mononuclear Ruthenium (II) Compounds, Letters in Drug Design & Discovery 2012; 9 (4) . https://dx.doi.org/10.2174/157018012799859927
DOI https://dx.doi.org/10.2174/157018012799859927 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Biological Effects of Curcumin and Its Role in Cancer Chemoprevention and Therapy
Anti-Cancer Agents in Medicinal Chemistry Modulation of GSTP1-1 Oligomerization by Electrophilic Inflammatory Mediators and Reactive Drugs
Inflammation & Allergy - Drug Targets (Discontinued) Antiproliferative Activity of Olive Oil Phenolics against Human Melan oma Cells
Letters in Drug Design & Discovery Interleukin-6: A Critical Cytokine in Cancer Multidrug Resistance
Current Pharmaceutical Design Applications of HPLC-MALDI-TOF MS/MS Phosphoproteomic Analysis in Oncological Clinical Diagnostics
Current Proteomics Target Acquired: Progress and Promise of Targeted Therapeutics in the Treatment of Prostate Cancer
Current Cancer Drug Targets Potential of Selected Antioxidants for Influenza Chemotherapy
Anti-Infective Agents in Medicinal Chemistry Reactive Oxygen Species: Physiological Roles in the Regulation of Vascular Cells
Current Molecular Medicine The Wnt/Beta-Catenin Pathway in Wilms Tumors and Prostate Cancers
Current Molecular Medicine Pancreatic Cancer and Personalized Medicine: Can Genomics Facilitate Early Diagnosis or Improve Therapeutic Outcomes?
Current Pharmacogenomics and Personalized Medicine Vitamin D Supplementation and Cancer: Review of Randomized Controlled Trials
Anti-Cancer Agents in Medicinal Chemistry The Rational Design of Anticancer Platinum Complexes: The Importance of the Structure-Activity Relationship
Current Medicinal Chemistry A Wnt-ow of Opportunity: Targeting the Wnt/β-Catenin Pathway in Breast Cancer
Current Drug Targets Role of Angiogenesis Inhibitors in Colorectal Cancer: Sensitive and Insensitive Tumors
Current Cancer Drug Targets Nonviral Vectors for Cancer Gene Therapy: Prospects for Integrating Vectors and Combination Therapies
Current Gene Therapy Structure, Roles and Inhibitors of a Mitotic Protein Kinase Haspin
Current Medicinal Chemistry Cytochrome P450-based Gene Therapy for Cancer Treatment: From Concept to the Clinic
Current Drug Metabolism Gastrointestinal Polyposis Syndromes
Current Molecular Medicine Phage Display Derived Therapeutic Antibodies
Current Pharmaceutical Biotechnology Lentiviral Vectors: A Versatile Tool to Fight Cancer
Current Molecular Medicine